SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-18-138793
Filing Date
2018-04-27
Accepted
2018-04-27 16:01:58
Documents
12
Period of Report
2018-06-18
Effectiveness Date
2018-04-27

Document Format Files

Seq Description Document Type Size
1 DEF 14A d506171ddef14a.htm DEF 14A 737061
2 GRAPHIC g506171g40b71.jpg GRAPHIC 6303
3 GRAPHIC g506171g50n20.jpg GRAPHIC 105764
4 GRAPHIC g506171g57t15.jpg GRAPHIC 27674
5 GRAPHIC g506171g88b19.jpg GRAPHIC 10691
6 GRAPHIC g506171img1.jpg GRAPHIC 47362
7 GRAPHIC g506171img2.jpg GRAPHIC 45280
8 GRAPHIC g506171img3.jpg GRAPHIC 9006
9 GRAPHIC g506171img4.jpg GRAPHIC 2048
10 GRAPHIC g506171new.jpg GRAPHIC 6326
11 GRAPHIC g506171new1.jpg GRAPHIC 20273
12 GRAPHIC g506171new2.jpg GRAPHIC 46788
  Complete submission text file 0001193125-18-138793.txt   1190703
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36274 | Film No.: 18783763
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences